key: cord-0705800-hkxerh0b authors: Grandvuillemin, Aurélie; Fresse, Audrey; Cholle, Clément; Yamani, Samir; Dautriche, Anne title: Adverse drug reactions of hydroxychloroquine: Analysis of French pre-pandemic SARS-CoV2 pharmacovigilance data date: 2020-05-05 journal: Therapie DOI: 10.1016/j.therap.2020.05.001 sha: 377a110dbc45de1333acf2ff5f8288efc7cc8cc6 doc_id: 705800 cord_uid: hkxerh0b nan Letter to the Editor after in utero exposure to chloroquine were published in 1969 [7] and 1 case of ocular abnormality in 2011 [8] in a child exposed prenatally to methotrexate and chloroquine. Two reviews of 12 and 9 studies [7, 9] including respectively 588 and 246 children did not highlight an increased risk of eye abnormalities in children exposed in utero to the two medications of interest. However, the authors of the reviews underlined the insufficiency of data, the presence of numerous biases and the need to follow up the children over a longer period. The ocular toxicity of these 2 drugs is dependent on the ''dose'' and the ''duration of use'' [10] . Considering the half-lives of these drugs, one cannot exclude, in case of a long exposure, their accumulation, favouring adverse effects on the retina. In conclusion, clinical data on chloroquine and hydroxychloroquine in pregnant women are rather reassuring when used in the indications of their marketing authorization. Some data exist with chloroquine when it is used against malaria. In other situations (other dosages, other durations of treatment, other indications), their benefit/risk balance is not established yet. These drugs can induce adverse effects, on the eyes (and a rare risk for the foetus cannot be entirely ruled out), but also on the heart rhythm (they are quinidine derivatives) that must increase our vigilance. In addition, chloroquine and potentially hydroxychloroquine are genotoxic. The use of these medications in pregnant women should therefore only be considered if the benefit of their use clearly justifies it. Given the half-lives of these drugs, it should also be remembered that a woman who took one of these 2 drugs will remain exposed up to 210 days for chloroquine and 420 days for hydroxychloroquine after stopping their intake. Thus, a woman who takes and stops one of these drugs before pregnancy can therefore be exposed during the upcoming pregnancy. In the case of exposure during pregnancy, as a precaution, careful ultrasound monitoring, increased vigilance at birth (especially in case of prematurity) and ophthalmological monitoring of the child should be recommended. Hydroxychloroquine (HCQ) is a 4-aminoquinoline derivative indicated in systemic lupus (SL), lucites and rheumatoid arthritis [1] . Its main adverse drug reactions (ADRs) described in the summary of product characteristics are ocular damage, particularly retinopathy during longterm exposure with high doses, cardiac damage with QT interval prolongation, cardiomyopathy during chronic treatment, potentially severe skin damage, neuromyopathy, haematological damage such as bone marrow aplasia and agranulocytosis. Several publications have focused on specific ADRs, particularly cardiac, auditory and ocular ones [2] [3] [4] but to date, to our knowledge, there are no published global pharmacovigilance data on ADRs reported in routine use with this drug. We performed a descriptive analysis of spontaneously reported ADRs. These ADRs were collected, analysed and recorded by the network of 31 French regional pharmacovigilance centres between January 1, 1985 (beginning of the French pharmacovigilance database) and December 31, 2019, i.e. before the use of this drug in the context of SARS-CoV2 pandemic. All reports where HCQ was coded as ''suspect'' or ''interaction'' were extracted from the French pharmacovigilance database. Causality assessment was performed according to the French causality assessment method [5, 6] . A total of 1717 reports were included, with 985 (57.4%) where HCQ was the only causal drug. These 1717 cases were reported over a period of 35 years (mean value of 50 reports per year), with more reports notified since 2012, reaching approximately 100 cases per year since 2016. Reporters were 90% physicians, 73% working in a health establishment. Less than 2% of reporters were patients or patient associations. The number of ''serious'' reports, according to World Health Organization (WHO) criteria, was 1022 (59.5%). The M/F sex ratio was 0.29 and mean age 50.8 ± 18.4 years. After excluding reports during pregnancy, 12 deaths were found. Five involved overdose and/or pharmacodependence to other products. The 7 other reports were 2 septic shocks, 1 pancytopenia, 4 cardiac ADRs (1 cardiac arrest at home after 4 years of exposure, 1 global cardiac failure after 1 year of treatment, 1 ventricular tachycardia on the 3rd day of treatment and 1 hypertrophic cardiomyopathy after 24 years of treatment). There was no overdose for these 4 cardiac ADRs. These 1717 reports described 2727 ADRs, mainly cutaneomucosal or immuno-allergic ones (32%). Other ADRs were found in less than 10% of reports: neurological (9%) [central and peripheral], haematological (8.5%), ocular (7.6%), digestive (6.7%) and cardiac (3.7%) disorders. However, when looking the 985 reports where HCQ was the only ''suspected'' drug, the frequency order was different, with the majority (34%) always involving mucocutaneous or immunoallergic disorders, followed by ocular (11%), neurological (10%), digestive (7.5%), hematological (5.1%) and cardiac (4.2%) ADRs. During the 1985-2019 period, there were 93 reports of cardiac ADRs (57 with HCQ the only ''suspected'' drug), 85% ''serious''. Sex ratio was 0.29 and mean age 53 ± 16 years. Approximately half of reports described development or aggravation of left ventricular failure, suggesting a sodium channel blocking effect of hydroxychloroquine. In some reports, regression or even disappearance of the cardiac ADR was observed after drug discontinuation. Approximately 22% of reports described symptoms suggestive of cardiac arrest or ventricular arrhythmia, half of which involved complex conduction disorders (9/21). This observation suggests that HCQ could block calcium but also especially voltage dependent potassium channels. Finally, rhythm and conduction disorders were found in 20% of reports in the French pharmacovigilance database. Analysis of French pharmacovigilance data makes it possible to define a safety profile of HCQ in patients treated for autoimmune diseases (only some isolated reports with off-label use were found). This paper underlines that the ADRs are mainly cutaneous, mucocutaneous and immuno-allergic. However, the detailed analysis found ''serious'' cardiac ADRs, that we related to HCQ after careful clinical analysis, taking into account suggestive chronology and semiology. As with any pharmacovigilance data, the figures given should not be minimised in view of the generally low reporting rate of ADRs. It is admitted that only 5-10% of ADRs are reported [7] . Spontaneous reporting depends on drug's age, perception of risk by healthcare professional or patient, seriousness of the reaction, lack of knowledge of some ADRs, diagnostic difficulties, etc. [6, 8] In our work, ''seriousness'' of the reports probably means that the much larger number of mild to moderate cases were never reported (and probably never detected). Therefore, these data shall be taken into account in risksbenefits balance of HCQ, in particular in situations where the clinical benefit is not proven. Keywords COVID-19; NSAID; Cyclooxygenase; Thrombosis; Acute renal failure; Prostaglandin angiotensin-converting enzyme 2 ARDs acute respiratory distress syndrome COVID-19 novel coronavirus disease 2019 COX cyclooxygenase NSAIDs non-steroidal anti-inflammatory drugs PG prostaglandin We read with great interest the article by Micallef J et al. ''Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection'' [1] . As the authors point out, non-steroidal anti-inflammatory drugs (NSAIDs) can lead to resistant superinfection during novel coronavirus disease 2019 (COVID-19) infection [1] . The risk of thrombosis and multiorgan failure is high in severe COVID-19 infec-tion. NSAIDs during COVID-19 infection can also lead to complications such as thrombosis and acute renal failure. We would like to mention several harmful effects of NSAIDs use during COVID-19 infection. The cyclooxygenase (COX) pathway plays a role in many physiological and pathophysiological events such as regulation of vascular tone, pulmonary fibrosis, and tissue remodeling, surfactant homeostasis, pulmonary defense, bronchial mucus secretion in the lung. By producing COX-2, prostaglandin (PG)E 2 , and PGI 2 , it is responsible for vasodilation, inflammation, fever, and pain. COVID-19 infection spreads rapidly all over the world and causes deaths. Recently published several articles reported that ibuprofen increased angiotensin-converting enzyme 2 (ACE2). ADAM17 is a metalloprotease that causes ACE2 shedding and thus ACE2 upregulation. ADAM17 activation may increase COVID-19 infection [2] . Non-selective NSAIDs activate ADAM17, causing ACE2 shedding [3] . NSAIDs can increase viral load in this way. Selective or non-selective NSAIDs two-fold or greater increase the risk of venous thromboembolism [4] . NSAIDs increase the risk of not only venous but also arterial thromboembolism [4] . PGI 2 inhibition, which has an antithrombotic effect with COX-2 inhibition, may increase the thrombosis risk [5] . Thrombosis tendency is higher in COX-2 selective inhibitors. COX-2 suppression disrupts thromboxane A 2 /PGI 2 balance in favor of thromboxane A 2 . By suppressing COX-1 over 95%, an antithrombotic effect occurs. Only aspirin or high-dose naproxen may perform this antithrombotic effect [5] . NSAIDs inhibit PG synthesis, leading to the Na + /K + exchanger (NHE) activation. Activation of NHE increases the thrombosis risk. The risk of arterial and venous thromboembolism is increased during COVID-19 infection. COVID-19 infection enhances the von Willebrand factor release by infecting the vascular endothelium, increasing the thrombosis risk [6] . Also, ACE2 becomes dysfunctional when the virus binds to ACE2. Since ACE2 degrades angiotensin II, ACE2's dysfunction increases angiotensin II levels. Angiotensin II activates NHE and NHE activation also shows a procoagulant effect. Angiotensin II binds to AT1 receptors, leading to increased levels of endothelin 1 and bradykinin [7] . Increased endothelium 1 pathway activates the coagulation cascade. Bradykinin increases the tendency of arterial thrombosis [7] . In addition, angiotensin IV formation increases because of elevated angiotensin II. When angiotensin IV levels increase excessively, angiotensin IV binds to AT1 receptors, causing thrombotic effects [8] . The risk of arterial and venous thromboembolism is already increased in COVID-19 infection, using NSAIDs in infected patients with the virus may more increase the embolism risk. COX-1 primarily functions in the control of kidney hemodynamics and glomerular filtration rate, while COX-2 functions principally affect salt and water excretion. COX-2inhibition enhances the pressure effect of angiotensin II [9] . NSAIDs increase blood pressure by causing sodium and water retention. Besides, they cause vasoconstriction by decreasing the formation of vasodilator prostacyclin in the vascular wall [5] . NSAIDs can lead to acute and chronic kidney failure. Angiotensin II level in patients with COVID-19 increased with the mechanisms mentioned above. COX inhibition due to NSAID use potentializes the negative effects of angiotensin Safety of chloroquine in chemosuppression of malaria during pregnancy The effects of quinine and chloroquine antimalarial treatments in the first trimester of pregnancy Comparison of intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during pregnancy in Mali Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: A systematic review and meta-analysis Hydroxychloroquine for the prevention of fetal growth restriction and prematurity in lupus pregnancy: a systematic review and meta-analysis Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature The Peters anomaly following antenatal exposure to methotrexate and hydroxychloroquine Hydroxychloroquine during pregnancy: a review of retinal toxicity in the newborns Hydroxychloroquine:. balancing the need to maintain therapeutic levels with ocular safety: an update Base de données publique des médicaments Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature Retinal toxicity associated with chronic exposure to hydroxychloroquine and its ocular screening. Review Hydroxychloroquine-induced hearing loss: first case of positive rechallenge and analysis of the French pharmacovigilance database Causality assessment in pharmacovigilance: the French method and its successive updates Pharmacovigilance -The next chapter Under-reporting of adverse drug reactions: a systematic review Reasons for reporting adverse drug reactions-some thoughts based on an international review French Pharmacovigilance Centres for data collection -Pascal Auriche (ANSM) for database extraction. The opinions expressed in this study are those of the authors and do not represent the views of ANSM. The authors declare that they have no competing interest.